SEAGULL HEALTH
Your health,We care!
Its core features are potent and highly selective ALK inhibition, excellent brain metastasis control, multi-target efficacy expansion and controllable safety.
AuthenticGuaranteeFast DeliveryPrivacy Ensartinib Hydrochloride Capsules (Trade Name: Beimeina) is a second-generation oral targeted anticancer drug of the ALK inhibitor class independently developed in China.
It is primarily indicated for the treatment of anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), covering both first-line therapy and second-line therapy scenarios in patients with disease progression or intolerance to crizotinib.
Ensartinib monotherapy is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
The recommended dose of ensartinib is 225mg once daily, to be taken orally at the same time each day, either on an empty stomach or with food. Treatment should be continued until disease progression or unacceptable toxicity occurs, provided that clinical benefit is observed.If a dose of ensartinib is missed and more than 12 hours remain before the next scheduled dose, the missed dose should be taken as soon as possible. In case of vomiting during treatment, no additional dose should be administered, and the next scheduled dose should be taken as planned.
Patients with hypersensitivity to the active ingredient ensartinib or any of the excipients.
At the dose level of 225mg, common adverse reactions include diseases of the skin and subcutaneous tissue (rash, pruritus, and other skin and subcutaneous tissue disorders), gastrointestinal disorders (nausea, constipation, vomiting, stomatitis, abdominal discomfort, and diarrhea), general disorders (edema, fatigue, and pyrexia), metabolic and nutritional disorders (decreased appetite and electrolyte imbalance), anemia, various musculoskeletal disorders, various infections, hyperbilirubinemia, diseases of the eye and adnexa, and cardiac arrhythmias.
Common laboratory test abnormalities include increased alanine aminotransferase, increased aspartate aminotransferase, increased serum creatinine, increased gamma-glutamyl transferase, other liver enzyme abnormalities, and abnormal blood cell counts.
For more detailed drug information, please consult the official package leaflet.
Ensartinib is an anaplastic lymphoma kinase (A···...【详情】
Ensartinib is a second-generation anaplastic l···...【详情】
The recommended usual dose of ensartinib is 22···...【详情】
Ensartinib is a targeted therapy for ALK-posit···...【详情】
If any issues arise, please contact us immediately.
Email:haiousales@gmail.com
Ensartinib is a second-generation targeted drug for anaplastic lymphoma kinase (ALK). It is mainly indicated for the treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). By inhibiting the kinase activity of ALK protein and blocking the growth signals of tumor cells, it has stronger target selectivity and the ability to cover some drug-resistant mutations.
Ensartinib is a prescription drug and must be purchased with an ALK-positive
gene detection report and a doctor's prescription.
Legitimate purchase channels include pharmacies of Grade A tertiary hospitals, medical insurance-designated pharmacies (e.g., dual-channel pharmacies in some regions), and legal online pharmaceutical platforms.
Yes, it can be mailed. Please provide a valid prescription. We will package and deliver the medicine in accordance with relevant regulations through compliant pharmaceutical logistics. We will ensure the safety of the medicine throughout the entire process and guarantee its timely delivery to you.
Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH
